Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)

Trial Profile

Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)

Completed
Phase of Trial: Phase II/III

Latest Information Update: 10 Dec 2015

At a glance

  • Drugs Mercaptamine bitartrate (Primary)
  • Indications Huntington's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms CYST-HD
  • Most Recent Events

    • 10 Dec 2015 Results of 36-month efficacy published in a Raptor Pharmaceuticals media release.
    • 06 Aug 2015 According to a Raptor media release, 36-month data from this study is expected to be reported in the fourth quarter of 2015.
    • 07 May 2015 According to a Raptor media release, 36-month data from this study is expected in second-half of 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top